Replies to post #14610 on Momenta Pharmaceuticals, Inc. (MNTA)

[stockbettor]

If the CAFC rules for MNTA, there’s a pretty good chance of a settlement to the Lovenox patent case—and all outstanding litigation with AMPH—IMO

Let's hope so. I have been tempted to reinvest in MNTA, especially at recent prices, but the enoxaparin litigation still vexes me. It's tough for me to accept the possibility that the Federal Circuit could award Amphastar damages for the MNTA patented IP that it stole. I also have no sense of how long the MNTA/Sandoz generic Copaxone will retain its status as the sole generic. However, I do think that MNTA's other programs represent an enticing investment.